Want to see JP:4896 full AI Analyst Report?

K Pharma,Inc. (4896) Price & Analysis

0 Followers

4896 Stock Chart & Stats

¥651.00

¥14.00(2.16%)

At close: Jan 08 4:00 PM EST

¥651.00

¥14.00(2.16%)

Day’s Range― - ―

52-Week Range¥604.00 - ¥949.00

Previous CloseN/A

Volume10.50K

Average Volume (3M)15.86K

Market Cap

¥9.32B

Enterprise Value¥7.25K

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta0.68

Next Earnings

Nov 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-20.84

Shares Outstanding11,622,600

10 Day Avg. Volume16,470

30 Day Avg. Volume15,860

Financial Highlights & Ratios

PEG Ratio-0.44

Price to Book (P/B)6.05

Price to Sales (P/S)0.00

P/FCF Ratio-8.24

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Prior Earnings CapabilityThe company demonstrated that it can generate meaningful revenue and positive earnings, providing evidence of commercial potential rather than a purely unproven model. Re-establishing that level of activity would offer a foundation for rebuilding operating leverage and investor confidence.

Improving Cash BurnAlthough cash flow remains negative, the modest improvement in 2025 indicates some movement toward better cash discipline or lower consumption. If sustained, reduced annual burn could extend financial flexibility and lessen the pace at which the company must seek additional funding.

Remaining Asset BaseMaintaining an asset base near ¥2.94B gives the company a tangible financial foundation while it works through its current operating weakness. This does not remove funding pressure, but it may support continued operations and provide resources for restoring revenue generation.

Bears Say

Revenue CollapseThe disappearance of reported revenue across two consecutive periods is a fundamental weakness, not a short-lived earnings fluctuation. It signals that the commercial engine is currently inactive, leaving the company without operating inflows to support development, overhead, or future growth.

Persistent LossesLarge operating and net losses while revenue is absent indicate that the current cost structure is not supported by business activity. Continued losses can erode capital, constrain investment choices, and make any recovery dependent on restoring revenue or obtaining additional financing.

Weakening Balance SheetShrinking equity combined with rising debt materially reduces financial flexibility. The higher leverage burden leaves less capital protection against further losses and increases the importance of a timely operating recovery, while potentially limiting the company’s ability to fund development internally.

4896 FAQ

What was K Pharma,Inc.’s price range in the past 12 months?

K Pharma,Inc. lowest stock price was ¥604.00 and its highest was ¥949.00 in the past 12 months.

What is K Pharma,Inc.’s market cap?

K Pharma,Inc.’s market cap is ¥9.32B.

When is K Pharma,Inc.’s upcoming earnings report date?

K Pharma,Inc.’s upcoming earnings report date is Nov 12, 2026 which is in 53 days.

How were K Pharma,Inc.’s earnings last quarter?

K Pharma,Inc. released its earnings results on Aug 13, 2026. The company reported -¥20.84 earnings per share for the quarter.

Is K Pharma,Inc. overvalued?

According to Wall Street analysts K Pharma,Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does K Pharma,Inc. pay dividends?

K Pharma,Inc. does not currently pay dividends.

What is K Pharma,Inc.’s EPS estimate?

K Pharma,Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does K Pharma,Inc. have?

K Pharma,Inc. has 11,622,600 shares outstanding.

What happened to K Pharma,Inc.’s price movement after its last earnings report?

K Pharma,Inc. reported an EPS of -¥20.84 in its last earnings report. Following the earnings report the stock price went up 2.937%.

Which hedge fund is a major shareholder of K Pharma,Inc.?

Currently, no hedge funds are holding shares in JP:4896

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

K Pharma,Inc.

K Pharma, Inc., headquartered in Minato, Japan, was established in 2016 and operates within the Japanese market. The company is dedicated to the research, development, production, and sale of both regenerative medicines and pharmaceutical products. A key focus within their regenerative medicine efforts involves leveraging disease-specific induced pluripotent stem (iPS) cell technology, primarily to develop treatments for conditions such as spinal cord injuries and cerebral infarctions.